Liver Transplantation Clinical Trial
Official title:
The Effect of Fluid Management Guided by Pulse Pressure Variation Versus Central Venous Pressure on Extra Vascular Lung Water Assessed by Lung Ultrasound Score During Liver Transplantation. A Randomized Controlled Trial.
the aim in this study to assess the effect of fluid management in patient undergoing orthotopic liver transplantation either by using pulse pressure variation or by central venous pressure. we will assess the impact of fluid management by either methods on oxygenation and extra vascular lung water visualized by lung ultrasound.
After induction of anesthesia lung ultrasound will be performed and arterial blood gases
(ABG) will be taken.
All patients in both groups will receive maintenance fluid in the form of crystalloids
(ringer acetate) 4 ml/kg/H. Then fluid boluses will be given according to each group:
Group c (cvp): will receive 250 ml albumin 5% boluses to maintain CVP around 5 cmH2o Group P
(ppv): will receive 250 ml albumin 5% boluses to maintain PPV below 13% as detected from
invasive blood pressure monitor.
For all patients in both groups: blood transfusion will be indicated with decreased HB% level
below 7 mg/dl in arterial blood gases. Other blood product (FFP, platelets and
cryoprecipitate) transfusion will be guided by lab results and clinical status of patient.
Plasma will be transfused if INR > 1.5 and platelets will be transfused if count < 50, 000
Lung ultrasound will be performed to diagnose EVLW. A Philips C5 ultrasound system (frequency
5Hz; Philips Medical Systems, Suresnes, France) with an ordinary echo probe will be used.
Chest ultrasound will be performed using the 12 regions method. Intercostals spaces on each
side will be examined anteriorly (midclavicular line), laterally (anterior axillary line) and
posteriorly (posterior axillary line) Four ultrasound aeration patterns a. Normal aeration
(N): 0 score ; line sliding sign associated with respiratory movement or less than 3 B lines
; b. Moderate loss of lung aeration: score 1 ; a clear number of multiple visible B-lines
with horizontal spacing between adjacent B lines ≤ 7 mm (B7 lines) c. Severe loss of lung
aeration: score 2; multiple B lines fused together that were difficult to count with
horizontal spacing between adjacent B lines ≤ 3 mm (B3 lines); and d. Pulmonary
consolidation: score 3; hyperechoic lung tissue, accompanied by dynamic air bronchogram.
The final LUS of the patient was the sum of each regional ultrasound score (ranging from 0 to
36).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04180735 -
Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
|
||
Completed |
NCT01011205 -
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
|
Phase 3 | |
Completed |
NCT01888432 -
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
|
Phase 3 | |
Recruiting |
NCT04203004 -
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
|
N/A | |
Recruiting |
NCT04564313 -
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
|
Phase 1 | |
Not yet recruiting |
NCT02544906 -
Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation
|
N/A | |
Withdrawn |
NCT03596970 -
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
|
Phase 3 | |
Completed |
NCT03133065 -
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
|
Phase 4 | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Terminated |
NCT01445236 -
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Completed |
NCT00938860 -
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
|
Phase 4 | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Completed |
NCT00456235 -
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
|
Phase 4 | |
Terminated |
NCT00585858 -
Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant
|
N/A | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Recruiting |
NCT00147459 -
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
|
N/A | |
Terminated |
NCT00161356 -
Ambisome in Liver Transplant Patients
|
Phase 4 | |
Withdrawn |
NCT00167492 -
Enteric Coated Myfortic for Liver Transplant Recipients
|
Phase 4 |